How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing

Published on June 17, 2026 at 11:16 am by Habib Ur Rehman in News

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects the bile ducts, gallbladder, or nearby digestive organs. In its May 5 first-quarter update, Compass said tovecimig had received FDA Orphan Drug Designation in April, a status meant for treatments targeting rare diseases. The company also said it planned to meet with the FDA ahead of a planned approval application later in 2026.

Compass is trying to move tovecimig toward regulators after a late-stage study showed stronger tumor response and longer disease control than chemotherapy alone. The company also said a Phase 1 study had begun for CTX-10726, another experimental cancer treatment, with initial data expected in the fourth quarter of 2026. Compass ended the first quarter with $195 million in cash and marketable securities, which it expects to fund operations into 2028. That gives the company time to push its lead cancer program through the next regulatory steps while also advancing earlier pipeline assets.